Email this article 
Updates of Cancer Immunotherapy: Review
Abstract
In the approach of Immune Checkpoint inhibitors (ICI) and of Chimeric antigen receptor T cells (CAR-T) supportive T-cells, the new outskirts in Oncology are Cancer Immunotherapy as a result of its capacity to give long term clinical advantage in metastatic disease in a several solid and liquid tumor types. It is currently evident that ICI acts by exposing preexisting immune reactions just as by instigating once more reactions against tumor neoantigens. Because of the progress made in genomics innovations and the advancement of bioinformatics, neoantigens address ideal focuses, because of their particular expression in cancer tissue and the possible absence of results. In this review, we talk about the guarantee of preclinical and clinical outcomes with change inferred neoantigen cancer vaccines (NCVs) alongside the current constraints from bioinformatics forecast to assembling a compelling new restorative methodology.
Keywords
Full Text:
PDFReferences
Anagnostou, Valsamo, et al. "Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer." Cancer discovery 7.3 (2017): 264-276.
Alexandrov, Ludmil B., et al. "Signatures of mutational processes in human cancer." Nature 500.7463 (2013): 415-421.
Zhao, Boyang, et al. "Exploiting temporal collateral sensitivity in tumor clonal evolution." Cell 165.1 (2016): 234-246.
Seliger, Barbara, Matthias Kloor, and Soldano Ferrone. "HLA class II antigen-processing pathway in tumors: molecular defects and clinical relevance." Oncoimmunology 6.2 (2017): e1171447.
Hu, Zhuting, Patrick A. Ott, and Catherine J. Wu. "Towards personalized, tumor-specific, therapeutic vaccines for cancer." Nature Reviews Immunology 18.3 (2018): 168.
Yarchoan, Mark, et al. "Targeting neoantigens to augment antitumor immunity." Nature Reviews Cancer 17.4 (2017): 209.
Aurisicchio, Luigi, et al. "The perfect personalized cancer therapy: cancer vaccines against neoantigens." Journal of Experimental & Clinical Cancer Research 37.1 (2018): 1-10.
Brown, Scott D., et al. "Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival." Genome research 24.5 (2014): 743-750.
Vickers, Neil J. "Animal communication: when I’m calling you, will you answer too?" Current biology 27.14 (2017): R713-R715.
Howitt, Brooke E., et al. "Association of polymerase e–mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1." JAMA oncology 1.9 (2015): 1319-1323.
Tran, Eric, Paul F. Robbins, and Steven A. Rosenberg. "'Final common pathway’ of human cancer immunotherapy: targeting random somatic mutations." Nature immunology 18.3 (2017): 255-262.
Li, Li, et al. "Autoimmune diabetes and thyroiditis complicating treatment with nivolumab." Case Reports in Oncology 10.1 (2017): 230-234.
Liu, David, et al. "Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma." Nature medicine 25.12 (2019): 1916-1927.
Rizvi, Naiyer A., et al. "Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer." Science 348.6230 (2015): 124-128.
- Le, Dung T., et al. "Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade." Science 357.6349 (2017): 409-413.
McGranahan, Nicholas, et al. "Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade." Science 351.6280 (2016): 1463-1469.
Strønen, Erlend, et al. "Targeting of cancer neoantigens with donor-derived T cell receptor repertoires." Science 352.6291 (2016): 1337-1341.
Tran, Eric, et al. "Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer." Science344.6184 (2014): 641-645.
Robbins, Paul F., et al. "Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells." Nature medicine 19.6 (2013): 747.
Boegel, Sebastian, et al. "HLA typing from RNA-Seq sequence reads." Genome medicine 4.12 (2013): 1-12.
Liu, X. Shirley, and Elaine R. Mardis. "Applications of immunogenomics to cancer." Cell 168.4 (2017): 600-612.
Kreiter, Sebastian, et al. "Mutant MHC class II epitopes drive therapeutic immune responses to cancer." Nature 520.7549 (2015): 692-696.
Yadav, Mahesh, et al. "Predicting immunogenic tumor mutations by combining mass spectrometry and exome sequencing." Nature 515.7528 (2014): 572-576.
Kuai, Rui, et al. "Designer vaccine nano discs for personalized cancer immunotherapy." Nature materials 16.4 (2017): 489-496.
Duan, Fei, et al. "Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity." Journal of Experimental Medicine 211.11 (2014): 2231-2248.
Gubin, Matthew M., et al. "Checkpoint blockade cancer immunotherapy targets tumor-specific mutant antigens." Nature515.7528 (2014): 577-581.
Schumacher, Theresa, et al. "A vaccine targeting mutant IDH1 induces antitumor immunity." Nature 512.7514 (2014): 324-327.
Kranz, Lena M., et al. "Systemic RNA delivery to dendritic cells exploits antiviral defense for cancer immunotherapy." Nature534.7607 (2016): 396-401.
Kranz, Lena M., et al. "Systemic RNA delivery to dendritic cells exploits antiviral defense for cancer immunotherapy." Nature534.7607 (2016): 396-401.
Martin, Spencer D., et al. "Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines." PloS one 11.5 (2016): e0155189.
Zolkind, Paul, et al. "Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma." Oncotarget 9.3 (2018): 4109.
Kim, Tae Jin, et al. "Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients." Nature communications 5.1 (2014): 1-14.
Trimble, Cornelia L., et al. "Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomized, double-blind, placebo-controlled phase 2b trial." The Lancet 386.10008 (2015): 2078-2088.
Morrow, Matthew P., et al. "Clinical and immunologic biomarkers for histologic regression of high-grade cervical dysplasia and clearance of HPV16 and HPV18 after immunotherapy." Clinical Cancer Research 24.2 (2018): 276-294.
Diaz, Claudia Marcela, et al. "Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors." Journal of translational medicine 11.1 (2013): 1-13.
Guo, Yugang, Kewen Lei, and Li Tang. "Neoantigen vaccine delivery for personalized anticancer immunotherapy." Frontiers in immunology 9 (2018): 1499.
Ott, Patrick A., et al. "An immunogenic personal neoantigen vaccine for patients with melanoma." Nature 547.7662 (2017): 217-221.
Sahin, Ugur, et al. "Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer." Nature 547.7662 (2017): 222-226.
Castel, Stephane E., et al. "Tools and best practices for data processing in allelic expression analysis." Genome biology 16.1 (2015): 1-12.
Boegel, Sebastian, et al. "HLA typing from RNA-Seq sequence reads." Genome medicine 4.12 (2013): 1-12.
Warren, René L., et al. "Derivation of HLA types from shotgun sequence datasets." Genome medicine 4.12 (2012): 1-8.
Shukla, Sachet A., et al. "Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes." Nature biotechnology 33.11 (2015): 1152-1158.
Tang, Shaojun, and Subha Madhavan. "neoantigenR: An annotation-based pipeline for tumor neoantigen identification from sequencing data." bioRxiv (2017): 171843.
Bhasin, Manoj, and G. P. S. Raghava. "Analysis and prediction of affinity of TAP binding peptides using cascade SVM." Protein Science 13.3 (2004): 596-607.
Hearn, Arron, Ian A. York, and Kenneth L. Rock. "The specificity of trimming of MHC class I-presented peptides in the endoplasmic reticulum." The Journal of Immunology 183.9 (2009): 5526-5536.
Zhang, Guang Lan, et al. "PRED TAP: a system for prediction of peptide binding to the human transporter associated with antigen processing." Immunome research 2.1 (2006): 1-12.
Chen, Hanna, et al. "ERAP1-ERAP2 dimers trim MHC I-bound precursor peptides; implications for understanding peptide editing." Scientific reports 6.1 (2016): 1-13.
Snyder, Alexandra, et al. "Genetic basis for clinical response to CTLA-4 blockade in melanoma." New England Journal of Medicine 371.23 (2014): 2189-2199.
Balachandran, Vinod P., et al. "Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer." Nature 551.7681 (2017): 512-516.
Burris, Howard A., et al. "A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors." (2019): 2523-2523.
Butts, Charles, et al. "Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomized, double-blind, phase 3 trial." The lancet oncology 15.1 (2014): 59-68.
Singer, Christian F., et al. "Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase II study (ABCSG 34)." European Journal of Cancer 132 (2020): 43-52.
Melief, Cornelis JM, et al. "Therapeutic cancer vaccines." The Journal of clinical investigation 125.9 (2015): 3401-3412.
Massarelli, Erminia, et al. "Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16–related cancer: a phase 2 clinical trial." JAMA oncology 5.1 (2019): 67-73.
Melief, Cornelis JM, et al. "Strong vaccine responses during chemotherapy are associated with prolonged cancer survival." Science translational medicine 12.535 (2020).
Fenstermaker, Robert A., et al. "Survivin monoclonal antibodies detect survivin cell surface expression and inhibit tumor growth in vivo." Clinical Cancer Research 24.11 (2018): 2642-2652. [57]- Fenstermaker, Robert A., et al. "Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma." Cancer Immunology, Immunotherapy 65.11 (2016): 1339-1352.
Ahluwalia, Manmeet Singh, et al. "SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update." J Clin Oncol 37. suppl 15 (2019): 2016.
Ostrom, Quinn T., et al. "Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014." JAMA oncology 4.9 (2018): 1254-1262.
Hanif, Ahmad, et al. "Exploring the role of survivin in neuroendocrine neoplasms." Oncotarget 11.23 (2020): 2246.
Andersen, Mads Hald. "The T-win® technology: immune-modulating vaccines." Seminars in immunopathology. Vol. 41. No. 1. Springer Berlin Heidelberg, 2019.
Andersen, Mads Hald. "Anti-regulatory T cells." Seminars in immunopathology. Vol. 39. No. 3. Springer Berlin Heidelberg, 2017.
Pedersen, Ayako Wakatsuki, et al. "Immunoregulatory antigens-novel targets for cancer immunotherapy." Chinese clinical oncology 7.2 (2018): 19-19.
Sørensen, Rikke Bæk, et al. "Indoleamine 2, 3-dioxygenase specific, cytotoxic T cells as immune regulators." Blood, The Journal of the American Society of Hematology 117.7 (2011): 2200-2210.
Munir, Shamaila, et al. "HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients." Cancer Research 73.6 (2013): 1764-1776.
Ahmad, S. M., I. M. Svane, and M. H. Andersen. "The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity." Blood cancer journal 4.7 (2014): e230-e230.
Munir, Shamaila, et al. "Natural CD4+ T-cell responses against indoleamine 2, 3-dioxygenase." PLoS One 7.4 (2012): e34568.
Munir, Shamaila, et al. "The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells." Oncoimmunology 2.4 (2013): e23991.
Andersen, Mads Hald. "Immune regulation by self-recognition: novel possibilities for anticancer immunotherapy." JNCI: Journal of the National Cancer Institute 107.9 (2015).
Kjeldsen, Julie Westerlin, et al. "Durable clinical responses and long-term follow-up of stage III–IV non-small-cell lung cancer (NSCLC) patients treated with IDO peptide vaccine in a Phase I study—a brief research report." Frontiers in immunology 9 (2018): 2145.
Dey, Souvik, et al. "Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses." Journal for immunotherapy of cancer 8.2 (2020).
Sahin, Ugur, et al. "Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer." Nature 547.7662 (2017): 222-226.
Ott, Patrick A., et al. "An immunogenic personal neoantigen vaccine for patients with melanoma." Nature 547.7662 (2017): 217-221.
Biotechnol, Nat. "The problem with neoantigen prediction." Nat Biotechnol 35 (2017): 97.
- Joshi, Kroopa, et al. "The “Achilles' Heel” of Cancer and its implications for the development of novel immunotherapeutic strategies." Cold Spring Harbor perspectives in medicine 8.1 (2018): a027086.
Jou, Jessica, et al. "The Changing Landscape of Therapeutic Cancer Vaccines—Novel Platforms and Neoantigen Identification." Clinical Cancer Research 27.3 (2021): 689-703.
Cohen, Roger B., et al. "A phase 1/2a study of GEN-009, a neoantigen vaccine based on autologous peptide immune responses." (2019): 2611-2611.
Cohen, Roger B., et al. "GEN-009, a neoantigen vaccine containing ATLAS selected neoantigens, to generate broad sustained immunity against immunogenic tumor mutations and avoid inhibitory peptides." (2020): 3107-3107.
BioNTech. Available from: https://biontech.de/science/individualized-cancermedicine.
Loquai, Carmen, et al. "A shared tumor-antigen RNA-lipoplex vaccine with/without anti-PD1 in patients with checkpoint-inhibition experienced melanoma." (2020): 3136-3136.
Braiteh, F., et al. "A phase Ia study to evaluate RO7198457, an individualized Neoantigen Specific immunotherapy (iNeST), in patients with locally advanced or metastatic solid tumors." Proceedings of the Annual Meeting of the American Association for Cancer Research. Vol. 2020. 2020.
Braiteh, F., et al. "A phase Ia study to evaluate RO7198457, an individualized Neoantigen Specific immunotherapy (iNeST), in patients with locally advanced or metastatic solid tumors." Proceedings of the Annual Meeting of the American Association for Cancer Research. Vol. 2020. 2020.
Moderna. Available from:https://www.modernatx.com/pipeline/therapeuticareas/immuno-oncology.
Rizvi, Naiyer A., et al. "Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer." Science 348.6230 (2015): 124-128.
Jou, Jessica, et al. "The Changing Landscape of Therapeutic Cancer Vaccines—Novel Platforms and Neoantigen Identification." Clinical Cancer Research 27.3 (2021): 689-703.
Hilf, Norbert, et al. "Actively personalized vaccination trial for newly diagnosed glioblastoma." Nature 565.7738 (2019): 240-245.
Peng, Weiyi, et al. "Loss of PTEN promotes resistance to T cell–mediated immunotherapy." Cancer discovery 6.2 (2016): 202-216.
Rizvi, Naiyer A., and Timothy A. Chan. "Immunotherapy and oncogenic pathways: the PTEN connection." Cancer discovery6.2 (2016): 128-129.
Milella, Michele, et al. "PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer." Scientific reports 7.1 (2017): 1-15.
Hugo, Willy, et al. "Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma." Cell165.1 (2016): 35-44.
George, Suzanne, et al. "Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma." Immunity 46.2 (2017): 197-204.
Gao, Jianjun, et al. "Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy." Cell167.2 (2016): 397-404.
Charoentong, Pornpimol, et al. "Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade." Cell reports 18.1 (2017): 248-262.
Peters, Solange, Keith M. Kerr, and Rolf Stahel. "PD-1 blockade in advanced NSCLC: A focus on pembrolizumab." Cancer treatment reviews 62 (2018): 39-49.
Sade-Feldman, Moshe, et al. "Resistance to checkpoint blockade therapy through inactivation of antigen presentation." Nature communications 8.1 (2017): 1-11.
DOI: http://dx.doi.org/10.52155/ijpsat.v26.2.3075
Refbacks
- There are currently no refbacks.
Copyright (c) 2021 Maged Naser, Mohamed M. Nasr, Lamia H. Shehata
This work is licensed under a Creative Commons Attribution 4.0 International License.